Literature DB >> 12017551

Reproductive functions of progesterone receptors.

Orla M Conneely1, Biserka Mulac-Jericevic, Francesco DeMayo, John P Lydon, Bert W O'Malley.   

Abstract

The steroid hormone progesterone plays a central role in the reproductive events associated with pregnancy establishment and maintenance. Physiological effects of progesterone are mediated by interaction of the hormone with specific intracellular progesterone receptors (PRs) that are expressed as two protein isoforms, PR-A and PR-B. Both proteins arise from the same gene and are members of the nuclear receptor superfamily of transcription factors. Since these two isoforms were identified in the early 1970s, extensive controversy has existed regarding the selective contributions of the individual PR proteins to the physiological functions of progesterone. During the past decade, significant progress has been made in this regard using two complimentary approaches. First, analysis of the structural and functional relationships of each isoform using in vitro systems has generated compelling evidence to support the conclusion that PR-A and PR-B have different transcription activation properties when liganded to progesterone. Second, the advent of gene-targeting approaches to introduce subtle mutations into the mouse genome has facilitated the evaluation of the significance of observations made in vitro in a physiological context. Selective ablation of PR-A and PR-B proteins in mice using these technologies has allowed us to address the spatiotemporal expression and contribution of the individual PR isoforms to the pleiotropic reproductive activities of progesterone. Analysis of the phenotypic consequences of these mutations on female reproductive function has provided proof of concept that the distinct transcriptional responses to PR-A and PR-B observed in cell-based transactivation assays are, indeed, reflected in an ability of the individual isoforms to elicit distinct, physiological responses to progesterone. In PR-A knockout mice, in which the expression of the PR-A isoform is selectively ablated (PRAKO), the PR-B isoform functions in a tissue-specific manner to mediate a subset of the reproductive functions of PRs. Ablation of PR-A does not affect responses of the mammary gland or thymus to progesterone but instead results in severe abnormalities in ovarian and uterine function, leading to female infertility. These tissue-selective activities of PR-B are due to this isoform's ability to regulate a subset of progesterone-responsive target genes in reproductive tissues rather than to differences in its spatiotemporal expression relative to the PR-A isoform. More recent studies using PR-B knockout (PRBKO) mice have shown that ablation of PR-B does not affect ovarian, uterine, or thymic responses to progesterone but rather results in reduced mammary ductal morphogenesis. Thus, PR-A is both necessary and sufficient to elicit the progesterone-dependent reproductive responses necessary for female fertility, while PR-B is required to elicit normal proliferative responses of the mammary gland to progesterone. This chapter will summarize recent progress in our understanding of the selective contribution of the two PR isoforms to progesterone action.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2002        PMID: 12017551     DOI: 10.1210/rp.57.1.339

Source DB:  PubMed          Journal:  Recent Prog Horm Res        ISSN: 0079-9963


  90 in total

1.  Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland.

Authors:  Guojun Cheng; Zhang Weihua; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

Review 2.  Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface.

Authors:  Kristy Red-Horse; Yan Zhou; Olga Genbacev; Akraporn Prakobphol; Russell Foulk; Michael McMaster; Susan J Fisher
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

Review 3.  Activation of progestin receptors in female reproductive behavior: Interactions with neurotransmitters.

Authors:  Shaila Mani; Wendy Portillo
Journal:  Front Neuroendocrinol       Date:  2010-01-29       Impact factor: 8.606

Review 4.  Minireview: Switching on progesterone receptor expression with duplex RNA.

Authors:  Bethany A Janowski; David R Corey
Journal:  Mol Endocrinol       Date:  2010-06-30

5.  Inhibition of apoptosis by progesterone in cardiomyocytes.

Authors:  Stephen Morrissy; Beibei Xu; David Aguilar; Jack Zhang; Qin M Chen
Journal:  Aging Cell       Date:  2010-10       Impact factor: 9.304

6.  Ricinus communis L. stem bark extracts regulate ovarian cell functions and secretory activity and their response to Luteinising hormone.

Authors:  S Nath; A Kadasi; R Grossmann; A V Sirotkin; A Kolesarova; A D Talukdar; M D Choudhury
Journal:  Int J Impot Res       Date:  2015-08-27       Impact factor: 2.896

Review 7.  The Effect of Menopausal Hormone Therapies on Breast Cancer: Avoiding the Risk.

Authors:  Valerie A Flores; Hugh S Taylor
Journal:  Endocrinol Metab Clin North Am       Date:  2015-06-23       Impact factor: 4.741

8.  Pregnancy without progesterone in horses defines a second endogenous biopotent progesterone receptor agonist, 5α-dihydroprogesterone.

Authors:  Elizabeth L Scholtz; Shweta Krishnan; Barry A Ball; C Jo Corbin; Benjamin C Moeller; Scott D Stanley; Karen J McDowell; Austin L Hughes; Donald P McDonnell; Alan J Conley
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

9.  ERBB receptor feedback inhibitor 1 regulation of estrogen receptor activity is critical for uterine implantation in mice.

Authors:  Tae Hoon Kim; Dong-Kee Lee; Heather L Franco; John P Lydon; Jae-Wook Jeong
Journal:  Biol Reprod       Date:  2009-12-16       Impact factor: 4.285

10.  Response of the ABCG2 promoter in T47D cells and BeWo cells to sex hormone treatment.

Authors:  Satoru Yasuda; Masaki Kobayashi; Shirou Itagaki; Takeshi Hirano; Ken Iseki
Journal:  Mol Biol Rep       Date:  2008-11-08       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.